4//SEC Filing
Ben-Tzvi Avraham 4
Accession 0000921895-25-002721
CIK 0000910267other
Filed
Oct 7, 8:00 PM ET
Accepted
Oct 8, 8:21 PM ET
Size
10.1 KB
Accession
0000921895-25-002721
Insider Transaction Report
Form 4
Ben-Tzvi Avraham
Director
Transactions
- Disposition to Issuer
Common Stock
2025-10-01−3,313→ 0 total - Disposition to Issuer
Option to Purchase Common Stock
2025-10-01−1,250→ 0 total→ Common Stock (1,250 underlying) - Disposition to Issuer
Option to Purchase Common Stock
2025-10-01−5,000→ 0 total→ Common Stock (5,000 underlying)
Footnotes (3)
- [F1]Disposed of pursuant to the Merger and Contribution and Share Exchange Agreement, dated as of August 19, 2024 (the "Merger Agreement"), by and among Titan Pharmaceuticals, Inc. ("Titan"), Black Titan Corporation ("Black Titan"), TTNP Merger Sub, Inc., a direct wholly owned subsidiary of Black Titan ("Merger Sub") and TalenTec Sdn. Bhd, in exchange for 1 ordinary share of Black Titan common stock for each share of Titan common stock on the effective date of the merger (the "Merger").
- [F2]Options issued pursuant to Titan's 2015 Omnibus Equity Incentive Plan with an exercise price equal to the closing price of Titan's common stock on August 15, 2022. These options were assumed by Black Titan in the Merger and exchanged for 1 Black Titan option for each Titan option.
- [F3]Options issued pursuant to Titan's 2015 Omnibus Equity Incentive Plan with an exercise price equal to the closing price of Titan's common stock on September 15, 2022. These options were assumed by Black Titan in the Merger and exchanged for 1 Black Titan option for each Titan option.
Documents
Issuer
TITAN PHARMACEUTICALS INC
CIK 0000910267
Entity typeother
Related Parties
1- filerCIK 0001944721
Filing Metadata
- Form type
- 4
- Filed
- Oct 7, 8:00 PM ET
- Accepted
- Oct 8, 8:21 PM ET
- Size
- 10.1 KB